Mark Connor

University of Sydney, Camperdown, New South Wales, Australia 
Trigeminal sensory neurons, opioid receptors, ion channels, cannabinoids
"Mark Connor"
Mean distance: 14.67 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Manandhar P, Connor M, Santiago M. (2022) Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone. Pharmacology Research & Perspectives. 10: e00921
Manandhar P, Murnion BP, Grimsey NL, et al. (2021) Do gabapentin or pregabalin directly modulate the µ receptor? Peerj. 9: e11175
Heblinski M, Santiago M, Fletcher C, et al. (2020) Terpenoids Commonly Found in Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. Cannabis and Cannabinoid Research. 5: 305-317
Gillis A, Gondin AB, Kliewer A, et al. (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling. 13
Sachdev S, Banister SD, Santiago M, et al. (2020) Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research & Perspectives. 8: e00566
Sachdev S, Boyd R, Grimsey NL, et al. (2019) Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells. Peerj. 7: e7733
Sachdev S, Vemuri K, Banister SD, et al. (2019) In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. British Journal of Pharmacology
Udoh M, Santiago M, Devenish S, et al. (2019) Cannabichromene is a cannabinoid CB2 receptor agonist. British Journal of Pharmacology
Moir M, Lane S, Lai F, et al. (2019) Strategies to develop selective CB receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry. 180: 291-309
Kevin RC, Anderson L, McGregor IS, et al. (2019) CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. Frontiers in Pharmacology. 10: 595
See more...